In collaboration with HDT Biotech Corporation, Seattle, USA, Gennova has developed an mRNA vaccine candidate (HGCO19), with demonstrated safety, immunogenicity, neutralization antibody activity in the rodent and non-human primate models. The company is working aggressively to ensure first human injection by the end of the year, subject to Indian regulatory approvals. mRNA-1273 is the working name of Moderna’s vaccine, which is currently in Phase 1 clinical trials under the aegis of the US National Institute of Allergy and Infectious Diseases (NIAID).

• The mRNA means messenger RNA, which carries the genetic formula for the coding of a specific protein. 
• The vaccine, when injected into a person for coding the spike protein, then even without the introduction of an attenuated (recognisable but not harmful) virus into the body, the body learns what the virus looks like and arms itself with the antibodies that are required to act against it.
• The mRNA while entering the body has managed to show an immune response in the first eight patients. 
• The results showed that even lower doses brought an immune response to the magnitude caused by natural infection.
• These data indicate that mRNA-1273 has the potential to prevent Covid-19 disease.